Loading clinical trials...
Loading clinical trials...
This trial is conducted in the United States of America (USA). The aim of this trial is to compare the effect of repaglinide on postprandial lipemia in subjects with type 2 diabetes.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novo Nordisk A/S
NCT07659535 · Type 2 Diabetes
NCT07102043 · Cystic Fibrosis Related Diabetes
NCT05124808 · Gestational Diabetes, Pregnancy, High Risk, and more
NCT07590193 · Diabetes Mellitus, Type 2
NCT06574035 · Diabetes Mellitus, Type 2, Depressive Symptoms, and more
Novo Nordisk Investigational Site
Houston, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions